OOIR: Observatory of International Research

Papers

(The TQCC of Cancer Biology & Medicine is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Eliminating cervical cancer: a global health imperative for women	222
Drugging the ‘undruggable’ KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer	128
Artificial intelligence in breast cancer: applications and advancements	82
Lactate drives immune resistance via a pharmaceutically reversible H3K18la-KIF20A-c-Myc-PD-L1 axis in hepatocellular carcinoma	66
A foundation model-enhanced CT radiomics signature for the noninvasive assessment of tertiary lymphoid structures and prediction of therapy benefit in gastric cancer	55
Early-onset gastric cancer global burden profile, trends, and contributors	54
Unraveling vascular mechanisms in melanoma: roles of angiogenesis and vasculogenic mimicry in tumor progression and therapeutic resistance	53
Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy	51
The Warburg effect drives dedifferentiation through epigenetic reprogramming	47
Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up	46
Mitochondrial transplantation sensitizes chemotherapy to inhibit tumor development by enhancing anti-tumor immunity	44
Click chemistry-driven tumor theranostics: recent advances, challenges, and future perspectives	42
Role of the tumor microenvironment in shaping IDH-wildtype glioma plasticity, and potential therapeutic strategies	37
Cancer stem cells: a target for overcoming therapeutic resistance and relapse	35
Stability and variability of molecular subtypes: comparative analysis of primary and metastatic triple-negative breast cancer	35
Cancer-derived exosomal circTMEM56 enhances the efficacy of HCC radiotherapy through the miR-136-5p/STING axis	33
PD-1 inhibitors provide new opportunities in conversion therapy for stage IV gastric cancer	31
Tumor-resident bacteria in gastrointestinal cancers: from regulatory mechanisms to clinical implications	31
Associations between polymorphisms in leptin and leptin receptor genes and colorectal cancer survival	31
Immune checkpoint inhibitors: breakthroughs in cancer treatment	29
The role of radiomics in predicting the response to neoadjuvant chemotherapy for breast cancer	28
Chinese expert consensus on additional surgery following endoscopic resection for early colorectal cancer (2025 edition)	27
Biological mechanism and immune response of MHC-II expression in tumor cells	27
Lung cancer mortality trends in China from 2013 to 2021 and projections to 2030	26
Optimizing the cancer research landscape for the benefit of patients and society: A strategic perspective of the German Cancer Research Center (DKFZ) and its partnerships with university medical cente	25

Chinese Society of Clinical Oncology Non-small Cell Lung Cancer (CSCO NSCLC) guidelines in 2024: key update on the management of early and locally advanced NSCLC	25
Non-coding RNA delivery via lipid nanoparticles: a novel strategy for cancer immunotherapy	23
ACSL3 regulates breast cancer progression via lipid metabolism reprogramming and the YES1/YAP axis	23
Cancer cell-derived migrasomes harboring ATF6 promote breast cancer brain metastasis via endoplasmic reticulum stress-mediated disruption of the blood-brain barrier	23
ENO1 expression and Erk phosphorylation in PDAC and their effects on tumor cell apoptosis in a hypoxic microenvironment	23
Effects of Helicobacter pylori eradication on the profiles of blood metabolites and their associations with the progression of gastric lesions: a	22
A machine learning model to predict efficacy of neoadjuvant therapy in breast cancer based on dynamic changes in systemic immunity	22
Pyroptosis in cancer: a dual regulator of tumor cell fate and immune activation	21
Nodal peripheral T-cell lymphomas in the new classification systems	21
Advances in lung cancer screening and early detection	21
Human papillomavirus vaccination willingness under resource inequities: momentary intervention effects of an educational video	21
Mitochondrial uncoupling inhibits serine catabolism via FTO activation in metastatic breast cancer	21
Glofitamab vs. real-world regimens in Chinese patients with third- or later-line relapsed/refractory diffuse large B-cell lymphoma: an external control study	20
Progress toward cervical cancer elimination: global disparities and China’s contributions	20
Facing challenges with hope: universal immune cells for hematologic malignancies	20
SPRED2 suppresses the stemness of hepatocellular carcinoma through the p53/miR-506-3p/KLF4 pathway	18
Enhancing cancer immunotherapy through polymer-based antibody conjugation technologies	17
From overtreatment to precision: a new clinical standard for DCIS management	17
Expert consensus on the detection and clinical application of tumor mutational burden	16
Ubiquitination in osteosarcoma: unveiling the impact on cell biology and therapeutic strategies	16
Biological insights in non-small cell lung cancer	15
Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study	15
Intricate roles of estrogen and estrogen receptors in digestive system cancers: a systematic review	15
Artificial intelligence-based comprehensive analysis of immune-stemness-tumor budding profile to predict survival of patients with pancreatic adenocarcinoma	14
Conceptualizing the complexity of ferroptosis to treat triple-negative breast cancer: theory-to-practice	14
A quick and reliable image-based AI algorithm for evaluating cellular senescence of gastric organoids	14
Evolution in single-cell proteomics drives new frontiers in cancer biology and precision medicine	14
First-line immunotherapy for advanced non-small cell lung cancer: current progress and future prospects	14
Elucidating the synergistic roles of CD4+ T and dendritic cells in antitumor immunity	14
Neutrophils as key regulators of tumor immunity that restrict immune checkpoint blockade in liver cancer	13
Current and future trends in whole genome sequencing in cancer	13
Chromatin relaxation dynamics and histone PTMs in the early DNA damage response	12
Single-cell and spatial transcriptome analyses reveal tumor immunometabolism in lymph node metastasis of lung cancer	12
Advances in antibody-drug conjugates for urothelial carcinoma treatment	12
Research progress in tumor angiogenesis and drug resistance in breast cancer	12
Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer	12
PD-1 and LAG-3 dual blockade: emerging mechanisms and potential therapeutic prospects in cancer	12
PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas	12
Immunological and metabolic optimization of tumor neoantigen vaccines	12
CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy	12
Liquid-liquid phase separation in DNA double-strand break repair	12
Treatment strategies for patients with HER2-positive gastric cancer	12
The role of intestinal flora on tumorigenesis, progression, and the efficacy of PD-1/PD-L1 antibodies in colorectal cancer	12
Major roles of the circadian clock in cancer	11
Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer	11
BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibi	11
Optimal immunotherapy duration in advanced NSCLC: defining the ideal treatment window	11
From dichotomy to diversity: deciphering the multifaceted roles of tumor-associated macrophages in cancer progression and therapy	11
Cancer risk in relatives of BRCA1/2 pathogenic variant carriers in a large series of unselected patients with breast cancer	11
Metabolic regulation of tumor-associated macrophage function and immunotherapy in cancer	11

Anti-tumor pharmacology of natural products targeting mitosis	11
Metabolic regulation of immune responses to cancer	10
Single-arm trials for domestic oncology drug approvals in China	10
Effectiveness of postoperative adjuvant radiochemotherapy versus radiotherapy in thoracic esophageal squamous cell carcinoma with lymph node metastasis: a multicenter randomized study	10
The evidence and concerns about screening ultrasound for breast cancer	10
Current status of management of immune-related adverse events and practical needs for oncologist education	10
Chidamide suppresses macrophage-mediated immune evasion and tumor progression in small cell lung cancer by targeting the STAT4/CCL2 signaling pathway	10
Integrative multi-omic analysis identified ERBB2 mutations and senescence-driven immune suppression as dual therapeutic targets in LAR triple-negative breast cancer	10
A causal variant rs3769823 in 2q33.1 involved in apoptosis pathway leading to a decreased risk of non-small cell lung cancer	10
Early detection of gastric cancer in China: progress and opportunities	9
Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy	9
The HDAC inhibitor GCJ-490A suppresses c-Met expression through IKKα and overcomes gefitinib resistance in non-small cell lung cancer	9
Expansion of IL-2-independent tumor-infiltrating lymphocytes through a feeder-free process: a preclinical study for solid tumors	9
Potential treatment approaches for malignant peritoneal mesothelioma: in vivo and in vitro experimental study of natural killer cell immunotherapy	9
Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification	9
Next-generation antibody–drug conjugates revolutionize the precise classification and treatment of HER2-expressing breast cancer	9
MicroRNA-384 radiosensitizes human non-small cell lung cancer by impairing DNA damage response and repair signaling, which is inhibited by NF-κB	9
Drug clinical trials on high-grade gliomas: challenges and hopes	9
Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer	9
Metabolic engineering of SLC38A2 reprograms glutamine utilization and enhances CAR-macrophage antitumor function in solid tumors	9
Epigenetic regulators as the foundation for molecular classification of colorectal cancer	8
Identifying occult high-risk features and stratified management strategies following curative resection for ampullary adenocarcinoma	8
Understanding the mechanisms underlying obesity in remodeling the breast tumor immune microenvironment: from the perspective of inflammation	8
Treatment strategies for advanced neuroendocrine neoplasms: current status and future prospects	8
Large-scale loss-of-function perturbations reveal a comprehensive epigenetic regulatory network in breast cancer	8
Erratum to DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors	8
Erianin inhibits the proliferation of lung cancer cells by suppressing mTOR activation and disrupting pyrimidine metabolism	8
Azoximer bromide and hydroxyapatite: promising immune adjuvants in cancer	8
Modeling cervical cancer elimination: a pathway to inform policy decisions	8
Virtual histology imaging of lymph nodes via dynamic full-field optical coherence tomography and deep learning to differentiate metastasis	7
Development of glioblastoma organoids and their applications in personalized therapy	7
Global, regional, and national burden of early-onset gastric cancer	7
Mutations in Ras homolog family member A in patients with peripheral T-cell lymphoma and implications for personalized medicine	7
Integrated pretreatment stratification system for pancreatic cancer: combining anatomical resectability and tumor biological parameters	7
Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma	7
Genomic medicine in clinical practice: national genomic medicine program in Japan	7
Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells	7
Erratum to Treatment strategies for patients with HER2-positive gastric cancer	7
Targeting PP2A for cancer therapeutic modulation	7
The inducible secreting TLR5 agonist, CBLB502, enhances the anti-tumor activity of CAR133-NK92 cells in colorectal cancer	7
Extracellular vesicle-mediated heterogeneous communication between cancer and the lymphatic system facilitates lymphatic metastasis	7
The evolution of cancer genomic medicine in Japan and the role of the National Cancer Center Japan	7
Neoantigen cancer vaccines: a new star on the horizon	7
Immunotherapy for multiple myeloma: new chances and hope	7
Senescent macrophages in cancer: roles in tumor progression and treatment opportunities	7
A therapeutic multi-epitope protein vaccine targeting HPV16 E6 E7 elicits potent tumor regression and cytotoxic immune responses	7
Microbiota-host interaction in colorectal cancer: emerging computational technology, multi-omics integration, and mechanisms	7
Animal models and pathogenesis of gastric cancer: from premalignant conditions-to-metastasis	7
Therapeutic perspectives for adult soft tissue sarcoma—updates from the 2022 ASCO annual meeting	7
Accelerating the elimination of global cervical cancer through intelligent training for colposcopy	7
Targeting tumor-infiltrating regulatory T cells based on immunometabolism	7